NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination yesterday stating its plans to stop covering the rheumatoid arthritis test Vectra DA and another draft proposal to extend coverage to Prolaris for patients at intermediate risk for prostate cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.